ALXO News and Press, ALX Oncology Holdings Inc. From 12/14/20

BURLINGAME, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the closing of its previously announced underwr...

The following slide deck was published by ALX Oncology Holdings Inc. in conjunction with this event. For further details see: ALX Oncology (ALXO) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Gainers: Sonoma Pharmaceuticals (SNOA) +87%.aTyr Pharma (LIFE) +65%.NantHealth (NH) +63%.vTv Therapeutics (VTVT) +55%.Equus Total Return (EQS) +45%Hancock Jaffe Laboratories (HJLI) +34%.MDJM (MDJH) +25%.Foresight Autonomous (FRSX) +23%.Solid Biosciences (SLDB) +22%.22...

Gainers: Sonoma Pharmaceuticals (SNOA) +114%. NantHealth (NH) +110%. vTv Therapeutics (VTVT) +59%. aTyr Pharma (LIFE) +33%. NantKwest (NK) +22%.Losers: SELLAS Life Sciences (SLS) -33%. Immutep (IMMP) -29%. Salarius Pharmaceuticals (SLRX) -29%. Nabriva Therapeutics (NBRV) -29%. ALX O...

In my 2020 outlook, which was pre-coronavirus, I argued the case for buying small and microcap medical stocks that were priced for "non-success". This approach worked in 2020. My 2020 themes were gene therapy, targeted oncologics, and less invasive surgery. For 2021, I add SARS CoV-2 ...

ALX Oncology (ALXO) has priced an upsized public offering of 2.38M common shares (from 2M) at $76.00/share, for expected gross proceeds of ~$180.9M.Underwriters' over-allotment is an additional 357K shares.Closing date is December 14.Shares up 4% after-hours. For further details s...

BURLINGAME, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the pricing of an upsized underwritten public o...

ALX Oncology (ALXO) has commenced an underwritten public offering of 2M shares of its common stock.Underwriters granted 30-day option to purchase up to an additional 300,000 shares.Press Release For further details see: ALX Oncology announces proposed public offering

BURLINGAME, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced that it has commenced an underwritten public of...

-- ORR of 70 .0 % Observed in Patients with NHL Treated with Higher Doses of ALX148 with Median Duration of Response Not Yet Reached -- Significant Improvement in Clinical Response Demonstrated with Increased ALX148 Exposure BURL...